Tag: oncology biomarkers market overview.

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Oncology Biomarkers Industry In 2025?

The oncology biomarkers market has seen a swift expansion recently, projected to increase its value from $15.3 billion in 2024 to $17.3 billion in 2025, reflecting a compound annual growth rate of 13.0%; this upswing during the past period stems from several factors, notably the uptake of these biomarkers in developing nations, ongoing precision medicine efforts, advancements in diagnostic technologies, crucial support for pharmaceutical research and development, and a higher prevalence of cancer cases overall.

Anticipation points toward substantial expansion in the oncology biomarkers market over the forthcoming years, with its valuation projected to reach $29.39 billion by 2029, reflecting a compound annual growth rate (CAGR) of 14.2%. This upward trajectory throughout the projection timeframe is fueled by several key factors, such as the incorporation of next-generation sequencing (NGS), the broadening scope of biomarker informatics, an increasing emphasis on predictive pharmacogenomics, swift advancements in exosome-based biomarkers, and the broader uptake of spatial transcriptomics. Key developments shaping this market during the forecast era encompass efforts toward standardization and quality assurance protocols, a discernible pivot toward functional biomass, the growing significance of biomarkers within clinical trials, augmented utilization in immunotherapy contexts, and the implementation of real-time monitoring for assessing treatment efficacy.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Oncology Biomarkers Industry?

Anticipation of an increase in cancer occurrences is forecasted to stimulate the expansion of the market for oncology biomarkers in the forthcoming period. Cancer is characterized by the runaway proliferation of specific bodily cells that subsequently infiltrate surrounding tissues throughout the physique. These oncological markers furnish deeper insights into the specific cancer type by examining constituents such as genes, proteins, and alternative substances present within an individual. To illustrate, data from the National Library of Medicine, a United States governmental organization, indicated in January 2024 that the United States is projected to see 2,001,140 new cancer diagnoses alongside 611,720 fatalities associated with the disease in the year 2024. Furthermore, an annual uptick of between 1% and 2% in the incidence rates for cervical cancer in the 30 to 44 age bracket and colorectal cancer among those younger than 55 has been observed in younger demographics. Consequently, this escalating prevalence of cancer is set to serve as a key impetus for the growth of the oncology biomarker sector.

How Is The Oncology Biomarkers Market Classified Into Different Segments?

The oncology biomarkersmarket covered in this report is segmented –

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Other Profiling Technologies

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

5) By End-User: Hospitals, Academic And Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers

2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)

3) By Other Cancer Biomarkers: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers

What Are The Major Trends Driving The Growth Of The Oncology Biomarkers Market?

A significant current in the oncology biomarker arena involves the embrace of novel and sophisticated technological solutions, with key industry players actively rolling out fresh, cutting-edge approaches to fortify their competitive standing within this market. As an illustration, consider the 2022 introduction by OncoDNA, a Belgian firm specializing in precision oncology, of OncoDEEP, a distinctive assay facilitating extensive biomarker evaluation within laboratory settings. This OncoDEEP system leverages Next-generation sequencing methodologies alongside software residing in the cloud, thereby equipping labs with the capacity to execute broad-panel sequencing, ascertain the complete molecular profile of a neoplasm, process the initial datasets, and utilize comprehensive quality assurance mechanisms.

Who Are The Prominent Global Companies Shaping The Oncology Biomarkers Market?

Major companies operating in the oncology biomarkers market include F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Eli Lilly and Company, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Charles River Laboratories International Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Bristol -Myers Squibb Company, Agendia Inc., Epigenomics AG, OncoDNA SA

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

How Do Regional Market Performances Compare Within The Oncology Biomarkers Industry?

North America was the largest region in the oncology biomarkers market in 2024. The regions covered in the oncology biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Oncology Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12493&type=smp

Browse Through More Reports Similar to the Global Oncology Biomarkers Market 2025, By The Business Research Company

Immuno Oncology Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

Interventional Oncology Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/interventional-oncology-devices-global-market-report

Oncology Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Oncology Biomarkers Market Grown from 2024 to 2025?

In recent times, there has been a swift expansion in the scale of the oncology biomarkers market. Estimated at $15.3 billion in 2024, it is projected to swell to $17.43 billion in 2025, showcasing a compound annual growth rate (CAGR) of 13.9%. The notable growth observed in the historic phase could be ascribed to wider acceptance in developing nations, efforts towards precision medicine, advancements in diagnostic procedures, support for drug development, and a rising occurrence of cancer.

What Growth Rate Is Anticipated for the Oncology Biomarkers Market in the Coming Years?

In the coming years, the oncology biomarkers market is projected to experience swift expansion. The market is anticipated to reach $29.64 billion by 2029, with a compound annual growth rate (CAGR) of 14.2%. Factors contributing to this predicted growth during the specified period include the integration of next-generation sequencing (ngs), the growth of biomarker informatics, emphasis on predictive pharmacogenomics, quick progression of exosome-based biomarkers, and the utilization of spatial transcriptomics. Key trends expected within this period are the standardization and quality assurance, a move towards functional biomarkers, the function of biomarkers in clinical trials, wider applications in immunotherapy, and real-time observation of therapy responses.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp

Who Are the Leading Companies in the Oncology Biomarkers Market?

Major companies operating in the oncology biomarkers market include F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Eli Lilly and Company, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Charles River Laboratories International Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Bristol -Myers Squibb Company, Agendia Inc., Epigenomics AG, OncoDNA SA

What Are the Key Drivers of the Oncology Biomarkers Market?

The oncology biomarker market is predicted to expand due to the increasing prevalence of cancer. This illness begins when some cells in the body start multiplying without control, gradually affecting the whole body. Oncology biomarkers help gain a deeper insight into the specific kind of cancer by evaluating the genes, proteins, and other substances present in a patient’s body. For instance, the National Library of Medicine, a government institution based in the US, projected in January 2024, that the United States might see 2,001,140 new cancer cases and 611,720 cancer-related fatalities in 2024. On top of that, the annual incidence rates of cervical cancer among individuals between 30 and 44 years old, and colorectal cancer in those under 55 years old, have been witnessing 1% to 2% increases among the younger population. Hence, the growing cancer prevalence is expected to steer the growth in the oncology biomarker market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12493&type=smp

What Are the Key Market Segments in the Oncology Biomarkers Industry?

The oncology biomarkers market covered in this report is segmented –

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Other Profiling Technologies

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

5) By End-User: Hospitals, Academic And Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers

2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)

3) By Other Cancer Biomarkers: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers

What Are the Latest Trends in the Oncology Biomarkers Market?

The trend of embracing groundbreaking and sophisticated technologies is prevalent in the oncology biomarker industry. To consolidate their market standing in the field of oncology biomarkers, top corporations are rolling out novel and pioneering technologies. A case in point is OncoDNA, a Belgium-based corporation specializing in precision medicine in oncology, which unveiled the OncoDEEP kit in 2022. This distinctive kit empowers laboratories to conduct thorough biomarker testing. Via the use of Next-generation sequencing (NGS) technology coupled with cloud-based software applications, OncoDEEP offers labs the means to carry out broad-panel sequencing, gain a molecular understanding of a tumor, scrutinize the raw data, and avail detailed quality control checks.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

What Are the Key Regional Markets in the Oncology Biomarkers Industry?

North America was the largest region in the oncology biomarkers market in 2024. The regions covered in the oncology biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12493

This Report Delivers Insight On:

1. How big is the oncology biomarkers market, and how is it changing globally?

2. Who are the major companies in the oncology biomarkers market, and how are they performing?

3. What are the key opportunities and risks in the oncology biomarkers market right now?

4. Which products or customer segments are growing the most in the oncology biomarkers market?

5. What factors are helping or slowing down the growth of the oncology biomarkers market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the oncology biomarkers industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Oncology Biomarkers Market In 2029?

In recent times, there has been a swift expansion in the scale of the oncology biomarkers market. Estimated at $15.3 billion in 2024, it is projected to swell to $17.43 billion in 2025, showcasing a compound annual growth rate (CAGR) of 13.9%. The notable growth observed in the historic phase could be ascribed to wider acceptance in developing nations, efforts towards precision medicine, advancements in diagnostic procedures, support for drug development, and a rising occurrence of cancer.

In the coming years, the oncology biomarkers market is projected to experience swift expansion. The market is anticipated to reach $29.64 billion by 2029, with a compound annual growth rate (CAGR) of 14.2%. Factors contributing to this predicted growth during the specified period include the integration of next-generation sequencing (ngs), the growth of biomarker informatics, emphasis on predictive pharmacogenomics, quick progression of exosome-based biomarkers, and the utilization of spatial transcriptomics. Key trends expected within this period are the standardization and quality assurance, a move towards functional biomarkers, the function of biomarkers in clinical trials, wider applications in immunotherapy, and real-time observation of therapy responses.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp

What are the Fundamental Drivers and Innovations Shaping the Oncology Biomarkers Market?

The oncology biomarker market is predicted to expand due to the increasing prevalence of cancer. This illness begins when some cells in the body start multiplying without control, gradually affecting the whole body. Oncology biomarkers help gain a deeper insight into the specific kind of cancer by evaluating the genes, proteins, and other substances present in a patient’s body. For instance, the National Library of Medicine, a government institution based in the US, projected in January 2024, that the United States might see 2,001,140 new cancer cases and 611,720 cancer-related fatalities in 2024. On top of that, the annual incidence rates of cervical cancer among individuals between 30 and 44 years old, and colorectal cancer in those under 55 years old, have been witnessing 1% to 2% increases among the younger population. Hence, the growing cancer prevalence is expected to steer the growth in the oncology biomarker market.

How Is the Oncology Biomarkers Market Segmented?

The oncology biomarkers market covered in this report is segmented –

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Other Profiling Technologies

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

5) By End-User: Hospitals, Academic And Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers

2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)

3) By Other Cancer Biomarkers: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12493&type=smp

Which Regions Are Driving the Next Phase of the Oncology Biomarkers Market Growth?

North America was the largest region in the oncology biomarkers market in 2024. The regions covered in the oncology biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Trends Are Shaping the Future of the Oncology Biomarkers Market?

The trend of embracing groundbreaking and sophisticated technologies is prevalent in the oncology biomarker industry. To consolidate their market standing in the field of oncology biomarkers, top corporations are rolling out novel and pioneering technologies. A case in point is OncoDNA, a Belgium-based corporation specializing in precision medicine in oncology, which unveiled the OncoDEEP kit in 2022. This distinctive kit empowers laboratories to conduct thorough biomarker testing. Via the use of Next-generation sequencing (NGS) technology coupled with cloud-based software applications, OncoDEEP offers labs the means to carry out broad-panel sequencing, gain a molecular understanding of a tumor, scrutinize the raw data, and avail detailed quality control checks.

View the full report here:

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

How Is the Oncology Biomarkers Market Defined and What Are Its Core Parameters?

Oncology biomarkers refer to biological indicators, such as genes, proteins, or other molecules, that can signal the presence of cancer or its progression. They are used to diagnose cancer, predict treatment responses, and monitor disease progression or recurrence. By analyzing these biomarkers, healthcare providers can tailor personalized treatment plans for patients.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12493

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers Contributing to the Growth and Expansion of the Oncology Biomarkers Market?

The increasing number of cancer cases is predicted to drive the growth of the oncology biomarker market. Cancer is characterized by the uncontrolled and gradual expansion of certain cells throughout the body. Oncology biomarkers help classify cancers by examining genes, proteins, and other substances within an individual. For example, the National Library of Medicine, a U.S.-based governmental agency, forecasts that there will be 2,001,140 new cancer diagnoses and 611,720 cancer-related deaths in the U.S. in 2024. Furthermore, the rate of cervical cancer in people between the ages of 30 to 44, along with colorectal cancer in individuals below 55, has increased by 1%-2% annually among young adults. As a result, the upward trend of cancer will fuel the oncology biomarker market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp

How Will the Growth Rate of theOncology Biomarkers Market Impact Industry Trends by 2034?

The market size for oncology biomarkers has seen a swift expansion in the preceding years. The market which stood at $15.3 billion in 2024, is projected to increase to $17.43 billion in 2025, showing a compound annual growth rate (CAGR) of 13.9%. The significant growth during the previous period is a result of adoption in emerging economies, implementation of precision medicine initiatives, innovative diagnostic approaches, support in drug development, and a rise in the incidence of cancer.

The market size of oncology biomarkers is predicted to experience a swift expansion in the upcoming years, reaching a value of $29.64 billion by 2029 with a compound annual growth rate (CAGR) of 14.2%. The anticipated growth during the forecast period is due to factors like the incorporation of next-generation sequencing (ngs), broadening of biomarker informatics, emphasis on predictive pharmacogenomics, the quick progression of exosome-based biomarkers, and the implementation of spatial transcriptomics. The forecast period will also witness significant trends such as standardization and quality assurance measures, shift towards functional biomarkers, the critical role biomarkers play in clinical trials, wide-ranging applications in immunotherapy, and real-time monitoring of treatment responses.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12493

What New Market Trends Are Reshaping theOncology Biomarkers Market and Its Opportunities?

The incorporation of cutting-edge and innovative technologies constitutes a critical trend in the oncology biomarker market. Leading businesses within this market are leveraging novel technologies as an instrumental strategy to consolidate their standing. For instance, OncoDNA, a Belgium-based company specializing in precision oncology medicine, rolled out OncoDEEP, a groundbreaking kit in 2022. This distinctive kit enables laboratories to carry out wide-scale biomarker testing. OncoDEEP deploys Next-generation sequencing (NGS) technology, coupled with cloud-based software tools, to equip laboratories with the capacity to conduct large-panel sequencing. This enables them to procure the molecular characterization of a tumour, process the raw data, and tap into comprehensive quality controls.

Who Are the Leading Market Players Fueling Growth in the Oncology Biomarkers Market Trend?

Major companies operating in the oncology biomarkers market include F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Eli Lilly and Company, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Charles River Laboratories International Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Bristol -Myers Squibb Company, Agendia Inc., Epigenomics AG, OncoDNA SA

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

How is the Global Oncology Biomarkers Market Segemented?

The oncology biomarkers market covered in this report is segmented –

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Other Profiling Technologies

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

5) By End-User: Hospitals, Academic And Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers

2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)

3) By Other Cancer Biomarkers: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12493&type=smp

Which Geographics are Influencing the Growth of the Oncology Biomarkers Market?

North America was the largest region in the oncology biomarkers market in 2024. The regions covered in the oncology biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Gobal Oncology Biomarkers Maret 2025, By The Business Research Company:

Community Oncology Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Immuno-Oncology Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

Clinical Oncology Next Generation Sequencing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the oncology biomarkers market grown in recent years?

The market size of oncology biomarkers has witnessed a rapid surge in the recent past. The growth is expected to continue, increasing from $15.3 billion in 2024 to $17.43 billion in 2025, thereby reflecting a compound annual growth rate (CAGR) of 13.9%. Factors such as wider acceptance in developing nations, precision medicine programs, advancements in diagnostics, support in drug development, and a rise in cancer cases have contributed to the growth during the historic period.

How is the oncology biomarkers market size expected to evolve during the forecast period?

Accelerated expansion is projected for the oncology biomarkers market in the coming years, with an expectation to reach a market value of $29.64 billion in 2029 and a compound annual growth rate (CAGR) of 14.2%. This upcoming surge can be credited to the incorporation of next-generation sequencing (ngs), enhancement of biomarker informatics, focus on predictive pharmacogenomics, swift progression in exosome-based biomarkers, as well as the acceptance of spatial transcriptomics. Key trends expected within this period encompass standardization and quality assurance, a shift towards functional biomarkers, the importance of biomarkers in clinical trials, increased utilities in immunotherapy, and real-time surveillance of treatment results.

Get your oncology biomarkers market report here!

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

Which key drivers are propelling the oncology biomarkers market’s growth?

The oncology biomarker market is poised for growth due to the surge in cancer cases. Uncontrolled growth and gradual spreading of some body cells characterize this disease. The insights on cancer types are obtained by examining the genes, proteins, and other substances in a person via oncological biomarkers. For example, the National Library of Medicine, a U.S. government institute, estimated in January 2024 that the U.S. would have 2,001,140 new cancer cases and 611,720 cancer-related fatalities in 2024. Moreover, the yearly increase of 1% to 2% has been observed in cervical cancer rates in the 30 to 44 age group and colorectal cancer in individuals under 55. Thus, the swelling cancer rates are set to bolster the oncology biomarker market’s growth.

What are the market segments in the oncology biomarkers industry?

The oncology biomarkers market covered in this report is segmented –

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Other Profiling Technologies

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

5) By End-User: Hospitals, Academic And Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers

2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)

3) By Other Cancer Biomarkers: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp

Which leading companies are shaping the growth of the oncology biomarkers market?

Major companies operating in the oncology biomarkers market include F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Eli Lilly and Company, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Charles River Laboratories International Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Bristol -Myers Squibb Company, Agendia Inc., Epigenomics AG, OncoDNA SA

What key trends are currently impacting the oncology biomarkers market’s development?

The introduction of cutting-edge and progressive technologies is a notable trend in the oncology biomarker sector. In their efforts to consolidate their standing, essential businesses in the oncology biomarkers market are employing innovative technology. To illustrate, OncoDNA, a precision medicine company based in Belgium that concentrates on oncology, pushed the envelope further in 2022 by rolling out OncoDEEP. This unique kit allows laboratories to undertake comprehensive biomarker examinations. It leverages Next-generation sequencing (NGS) technology in tandem with cloud-based software instruments to enable laboratories to perform large-panel sequencing, acquire a tumor’s molecular profile, interpret raw data, and tap into expansive quality controls.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12493

Which geographic areas are influencing the growth of the oncology biomarkers market?

North America was the largest region in the oncology biomarkers market in 2024. The regions covered in the oncology biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Community Oncology Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Immuno-Oncology Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

Clinical Oncology Next Generation Sequencing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Growth Potential of the Oncology Biomarkers Market, and How Will It Perform by 2034?

The oncology biomarkers market has expanded rapidly in recent years. It is forecasted to grow from $15.3 billion in 2024 to $17.43 billion in 2025, reflecting a CAGR of 13.9%. The key factors driving its historical growth include increased adoption in emerging economies, precision medicine initiatives, innovations in diagnostics, support for drug development, and a rising incidence of cancer.

The oncology biomarkers market is expected to witness rapid expansion, reaching $29.64 billion by 2029 with a CAGR of 14.2%. This growth will be propelled by the adoption of next-generation sequencing (NGS), advancements in biomarker informatics, a focus on predictive pharmacogenomics, swift developments in exosome-based biomarkers, and the increasing application of spatial transcriptomics. Key trends will include standardization and quality assurance initiatives, a shift toward functional biomarkers, their expanded role in clinical trials, increased applications in immunotherapy, and real-time monitoring of treatment responses.

What Industry-Specific Factors Are Fueling the Growth of the oncology biomarkers Market?

The rising incidence of cancer is expected to drive the growth of the oncology biomarker market. Oncological biomarkers offer insights into the type of cancer by analyzing genes, proteins, and other substances in the body. The National Library of Medicine projected in January 2024 that there will be 2,001,140 new cancer cases and 611,720 cancer-related deaths in the U.S. in 2024, leading to growth in the oncology biomarker market.

Request Your Free Oncology Biomarkers Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp

Who Are the Major Companies Shaping the Competitive Landscape of the Oncology Biomarkers Market?

Major companies operating in the oncology biomarkers market include:

• F Hoffmann-La Roche AG_x000D_

• Novartis AG_x000D_

• Thermo Fisher Scientific Inc._x000D_

• Abbott Laboratories_x000D_

• Eli Lilly and Company_x000D_

What Are the Key Emerging Trends in the Oncology Biomarkers Market for the Next Decade?

Adopting innovative technologies is a key trend in the oncology biomarker market. Companies in this sector are introducing new technologies to strengthen their market position. For example, in 2022, OncoDNA, a Belgium-based company focused on precision oncology, launched OncoDEEP, a kit that enables comprehensive biomarker testing. Using next-generation sequencing (NGS) and cloud-based tools, OncoDEEP allows laboratories to perform large-panel sequencing and analyze tumor molecular characteristics, ensuring accurate results and quality control.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

Which Key Market Segments Comprise the Oncology Biomarkers Market and Drive Its Revenue Growth?

The oncology biomarkers market covered in this report is segmented –

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Other Profiling Technologies

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

5) By End-User: Hospitals, Academic And Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers

2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)

3) By Other Cancer Biomarkers: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers

Which Regions Are Making a Mark in the Oncology Biomarkers Market Growth?

North America was the largest region in the oncology biomarkers market in 2024. The regions covered in the oncology biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Is the Oncology Biomarkers Market Categorized and Defined in the Industry?

Oncology biomarkers refer to biological indicators, such as genes, proteins, or other molecules, that can signal the presence of cancer or its progression. They are used to diagnose cancer, predict treatment responses, and monitor disease progression or recurrence. By analyzing these biomarkers, healthcare providers can tailor personalized treatment plans for patients.

Browse Through More Similar Reports By The Business Research Company:

Community Oncology Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Immuno-Oncology Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

Clinical Oncology Next Generation Sequencing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: